Medtronic PLC "Monthly Symplicity RDN Physician Data: Wave 4" (Neutral) Sachdeva

Research evidence excerpt

Medtronic PLC "Monthly Symplicity RDN Physician Data: Wave 4" (Neutral) Sachdeva

Powered by Lab Global10 JuneResearch2026ab Evidence UBS YES

Medtronic PLC Equities

United StatesMonthly Symplicity RDN Physician Data: Wave 4

Medical Supplies

12-month rating Neutral

Symplicity Physician Data Suggests Market Development Progressing

Our UBS Evidence Lab Data scrapes weekly physician counts on Medtronic's Symplicity 12m price target US$85.00

RDN Specialist website. As of the week ended June 6th, 2026, MDT has 249 listed

Symplicity specialists which represents a ~8.7% increase month/month (vs. end of 1st

Price (09 Jun 2026) US$81.98

full week of May). Our Evidence Lab data collection began on 2/21/2026. Renal

denervation (RDN) continues to build momentum as clinical evidence and real-world RIC: MDT.N BBG: MDT US

physician sentiment align following FDA approvals in late 2023.

Trading data and key metrics

52-wk range US$105.35-73.75

Our recent KOL channel checks suggest rising awareness and confidence in RDN Market cap. US$105b

as an adjunctive option for patients with uncontrolled or resistant hypertension,

Shares o/s 1,284m (COM)

driven by consistent sham-controlled trial data demonstrating durable blood pressure

Free float 100%

reductions and a favorable safety profile. Feedback indicates particular interest among

Avg. daily volume ('000) 2,410

interventional cardiologists and hypertension specialists, who increasingly view RDN as

complementary to pharmacologic therapy, especially for patients with adherence Avg. daily value (m) US$197.1

challenges or polypharmacy fatigue. While there is clear momentum, the key adoption Common s/h equity (04/26E) US$49.8b

levers to reach a growth inflection include 1) better patient selection, 2) reimbursement P/BV (04/26E) 2.1x